Overview

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

Status:
Completed
Trial end date:
2016-02-12
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy, pharmacokinetics (PK), and safety of icatibant for the treatment of acute attacks in Japanese participants with type I or type II hereditary angioedema (HAE).
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Bradykinin
Icatibant